10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing
23 avr. 2024 16h42 HE
|
10X Capital Venture Acquisition Corp. III
New York, NY, April 23, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by...
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Noncompliance
31 janv. 2024 17h16 HE
|
10X Capital Venture Acquisition Corp. III
New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB, VCXB.U, VCXB WS) (“10X III”), announced today that NYSE Regulation (“NYSER”), by...
10X Capital Venture Acquisition Corp. III Announces Expected Change in Management
08 janv. 2024 06h00 HE
|
10X Capital Venture Acquisition Corp. III
NEW YORK, NY (United States), Jan. 08, 2024 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (“10X III”) (NYSE American:VCXB), a publicly traded special purpose acquisition company,...
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
28 nov. 2023 16h10 HE
|
10X Capital Venture Acquisition Corp. III
New York, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB) (“10X III”), announced today that New York Stock Exchange Regulation, Inc., by letter...
10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American
04 oct. 2023 18h07 HE
|
10X Capital Venture Acquisition Corp. III
New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U, VCXB, VCXB WS) (“10X III”) today announced that it is transferring the listing of its Class A...
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
09 août 2023 21h07 HE
|
10X Capital Venture Acquisition Corp. III
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those...
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III
09 août 2023 19h02 HE
|
10X Capital Venture Acquisition Corp. III
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those...
SPARKS ENERGY, A LEADER IN POWER INFRASTRUCTURE SERVICES AND RESTORATION, TO LIST ON NEW YORK STOCK EXCHANGE THROUGH MERGER WITH 10X CAPITAL VENTURE ACQUISITION CORP. III
21 déc. 2022 07h00 HE
|
10X Capital Venture Acquisition Corp. III
Sparks Energy, Inc. (“Sparks”), a power infrastructure services firm and a leader in power restoration management, has entered into a merger agreement with 10X Capital Venture Acquisition Corp. III...
10X Capital Venture Acquisition Corp. III Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing March 4, 2022
01 mars 2022 16h05 HE
|
10X Capital Venture Acquisition Corp. III
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U) (the “Company”) today announced that, commencing March 4, 2022, holders of the units sold in the...
10X Capital Venture Acquisition Corp. III Announces Closing of Upsized $300 Million Initial Public Offering
14 janv. 2022 15h18 HE
|
10X Capital Venture Acquisition Corp. III
New York, NY , Jan. 14, 2022 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. III (NYSE: VCXB.U) (the “Company”) today announced that it closed its initial public offering of 30,000,000...